Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2009.

"We have now completed the clinical development program for Acetavance(TM), our proprietary formulation of intravenous acetaminophen for the treatment of acute pain and fever in adults and children, and plan to submit a New Drug Application for Acetavance in the second quarter of 2009," stated Ted Schroeder, President and CEO of Cadence Pharmaceuticals. "We also achieved another important corporate objective earlier this year by raising gross proceeds of $86.6 million through a private placement of common stock and warrants. We believe this additional capital strengthens our balance sheet and will enable us to prepare for the launch of Acetavance, if approved by the FDA."

In March 2009, Cadence announced that its Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections did not meet its primary endpoint and that, as a result, the company made the strategic decision to discontinue further development of this product candidate. In order to reduce operating costs following this decision, Cadence implemented a restructuring plan, including a workforce reduction.

First Quarter 2009 Financial Results

For the first quarter ended March 31, 2009, Cadence reported a net loss of $10.4 million, or $0.24 per share, compared to a net loss of $13.7 million, or $0.42 per share, for the same period in 2008. The per share amount for the first quarter of 2009 includes the effect of the issuance of 12,039,794 shares of common stock during the quarter pursuant to a private placement transaction and the issuance of 9,240,307 shares of common stock pursuant to a registered direct offering of common stock during the first quarter of 2008, while the per share amount for the first quarter of 2008 includes only the effect of the 2008 common stock issuance.

As of March 31, 2009, Cadence held cash and cash equivalents of $118.5 million, which included proceeds from the private placement of the company's common stock completed in February 2009, pursuant to which Cadence issued and sold approximately 12.0 million shares at a price of $7.13 per share and 6.0 million warrants, exercisable at $7.84 per share, at a price of $0.125 per warrant. The transaction resulted in proceeds, net of offering costs, of approximately $86.2 million.

Operating expenses for the first quarter ended March 31, 2009 were $10.1 million, a decrease of $3.7 million from the $13.8 million reported for the first quarter of 2008. This decrease was due to a reduction in research and development expenses during the three months ended March 31, 2009, as compared to the same period in 2008, partially offset by restructuring charges incurred as a result of the discontinuation of the company's Omigard development program in the first quarter of 2009. The reduction in research and development costs was primarily the result of reduced clinical research spending due to the completion of the company's clinical trials and reduced charges related to facility improvements at the company's contract manufacturer's facility. Partially offsetting these decreases were increases in costs incurred in preparing for the submission of the company's NDA for Acetavance.

Conference Call and Webcast on May 7, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)

Cadence management will host a conference call on May 7, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing 877-856-1961 (domestic) or 719-325-4792 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "expects," "anticipates," "plans," "will," and "assuming," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding: Cadence's belief that it has completed the clinical development program for Acetavance, the timeframe in which it expects to file a New Drug Application, or NDA, for Acetavance, the anticipated cost savings from the discontinuation of the company's Omigard development program, and the adequacy of Cadence's existing financial resources to enable it to successfully launch Acetavance. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: Cadence is largely dependent on the success of its only product candidate, Acetavance, and cannot be certain that this product candidate will receive regulatory approval or be successfully commercialized; clinical trial data may fail to adequately support the safety and efficacy of Acetavance, or the prevalence or severity of adverse side effects may be greater than anticipated, which could prevent or significantly delay its regulatory approval; if changes made in transferring the manufacturing process for Acetavance result in a lack of comparability between the commercial product and the material used in clinical trials, Cadence may be required to perform additional non-clinical or clinical studies, which would delay the approval of the NDA for Acetavance, increase costs and adversely affect the company's business; heightened scrutiny by the FDA in the process of approving new drugs could delay or limit the company's ability to obtain regulatory approval for Acetavance; Cadence may require substantial additional funding in order to obtain regulatory approval of Acetavance and, if approved, to successfully launch this product candidate, and the company may not be able to raise sufficient capital when needed, or at all, particularly in light of the recent, unprecedented volatility in the capital markets; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400

                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                       CONDENSED STATEMENTS OF OPERATIONS
                                  (unaudited)

                                                  Three Months Ended
                                                        March 31,
                                                  2009            2008
    Operating expenses:
      Research and development                $6,139,342    $10,478,047
      Marketing                                  536,115        583,702
      General and administrative               2,811,747      2,667,038
      Other                                      650,786         28,257
        Total operating expenses              10,137,990     13,757,044

    Loss from operations                     (10,137,990)   (13,757,044)

    Other (expense) income, net                 (299,373)        40,129

    Net loss                                $(10,437,363)  $(13,716,915)

    Basic and diluted net loss per share(1)       $(0.24)        $(0.42)

    Shares used to compute basic and
    diluted net loss per share(1)             43,831,889     32,921,093

    (1) As a result of the issuance of 12,039,794 shares of common stock
        pursuant to a private placement in the first quarter of 2009 and
        9,240,307 shares of common stock pursuant to an effective shelf
        registration in the first quarter of 2008, there is a lack of
        comparability in the per share amounts between the 2009 and 2008
        periods presented.


                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                             CONDENSED BALANCE SHEETS

                                                     March 31,   December 31,
                                                       2009          2008
                                                   (unaudited)
                      Assets
    Current assets:
      Cash and cash equivalents
                                                  $118,549,004   $47,627,246
      Restricted cash                                1,847,848     2,195,696
      Prepaid expenses and other current assets        312,801       219,674
        Total current assets                       120,709,653    50,042,616

    Property and equipment, net                      4,376,590     4,477,020
    Restricted cash                                    537,586       537,586
    Other assets                                        57,673        90,792
        Total assets                              $125,681,502   $55,148,014

            Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable                              $3,542,647    $4,877,854
      Accrued liabilities                            5,814,540     9,063,310
      Current portion of long-term debt              7,045,605     7,694,173
      Current current liabilities                       22,048        22,048
        Total current liabilities                   16,424,840    21,657,385

    Deferred rent                                      876,724       952,274
    Long-term debt, less current portion and
     discount                                        4,653,728     6,098,113
    Total stockholders' equity                     103,726,210    26,440,242
        Total liabilities and stockholders'
         equity                                   $125,681,502   $55,148,014


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
Breaking Biology News(10 mins):